| Type | Sym | Class | Transaction | Value $ | Shares | Change % | Price $ | Shares After | Date | Ownership | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|
| transaction | LLY | Common Stock | Sale | -$31.2 M | -41.1 K | -0.04% | $760.19 | 99.1 M | Feb 15, 2024 | Direct | F1 |
| transaction | LLY | Common Stock | Sale | -$5.99 M | -7.86 K | -0.01% | $761.56 | 99.1 M | Feb 15, 2024 | Direct | F2 |
| transaction | LLY | Common Stock | Sale | -$1.07 M | -1.4 K | 0% | $762.26 | 99.1 M | Feb 15, 2024 | Direct | F3 |
| Id | Content |
|---|---|
| F1 | The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $760.00 to $760.99, inclusive. The reporting person undertakes to provide to Eli Lilly & Company, any security holder of Eli Lilly & Company, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (1), (2), and (3) to this Form 4. |
| F2 | The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $761.02 to $762.00, inclusive. |
| F3 | The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $762.22 to $762.41, inclusive. |